Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This image is advertising the OBN Digital Event, An Update on Market Access into Europe, kindly hosted by The Netherlands Foreign Investment Agency. It is being held on Friday 18th September 2020 from 10:00 am to 11:00 am.

With the United Kingdom leaving the European Union, uncertainties remain for British biopharmaceutical companies in ensuring their European supply chain, market authorisation and funding. The event will give you an update on Market Access into Europe, with key speakers updating you on crucial topics for gaining or retaining European market access via the Netherlands.



This session will be moderated by Koen Daaman - Head of Stakeholder Management & Investor Relations, Life Sciences & Health Netherlands Foreign Investment Agency.

  • 'Supply Chain into Europe post-Brexit' - Jelle de Rooij, Senior Manager Supply Chain Solutions, Holland International Distribution Council.
  • 'Access to European public funding for UK companies' - Andrée Schram PhD, Advisor Life Sciences & Health and National contact point for H2020 and Horizon Europe, Netherlands Enterprise Agency.

'European biopharma market authorisation'


To register, click here